NEW YORK (GenomeWeb) – Interpace Diagnostics today said that it has regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholder equity.

As a result, the company's shares will remain listed on the Nasdaq Capital Market.

The firm was notified in November that it failed to meet the listing requirement and faced delisting action. On April 10, though, it received a letter from Nasdaq saying it had regained compliance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.